Lower-Risk Myelodysplastic Syndromes (LR-MDS): Highlights from EHA 2024 - Episode 12
Sequencing Second-Line Treatments for LR-MDS
Medical experts discuss sequencing strategies for second-line and later treatments in lower-risk myelodysplastic syndromes, examining how recent data, including insights from the MEDALIST trial, influence treatment selection and sequencing decisions.
- Let’s explore sequencing strategies for lower-risk MDS in the 2L setting and beyond. Discuss how new data and other considerations impact treatment selection and sequencing.
- Dr Komrokji: How do you approach treating patients with luspatercept from based on data from the MEDALIST trial? (Santini V, et al. ASH 2023. Abstract 915)
- What is the impact of fatigue events on overall treatment outcomes in patients treated with luspatercept for LR-MDS?
- Dr. Thomas Cluzeau: Based on the results from the MEDALIST trial, how would you approach dose escalation for 2L treatment of luspatercept in patients with LR-MDS? (Platzbecker U et al. Blood 2022)